Mark Ey, RPh, from NCPA, joins to discuss the opportunities for independent pharmacies within the ACCESS to Pharmacy Care Program.
|Articles|July 12, 2004
No agreement on serious drug interactions, study finds
A study found that less than 2% of 406 major drug-drug interactions were listed in all four national drug compendia and 71% were listed in only one of the expert sources.
Advertisement
Advertisement
Related to this article
Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
Advertisement
Advertisement
Trending on Drug Topics
1
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
2
Missouri Challenges Lilly’s 340B Data Policy: What Stakeholders Should Know
3
How Pharmacist-Led ART Protocol Improves HIV Medication Outcomes
4
Measles Cases Near 5000 in 2026 as Flu Season Starts Earlier Than Usual
5